GSK completes $3 billion acquisition of Human Genome

LONDON Fri Aug 3, 2012 2:14am EDT

Related Topics

LONDON (Reuters) - GlaxoSmithKline has completed its $3 billion acquisition of long-time biotech partner Human Genome Sciences, after buying all the outstanding shares for $14.25 each in cash, Britain's biggest drugmaker said on Friday.

The deal secures it full rights to recently launched lupus drug Benlysta and other experimental medicines.

(Reporting by Ben Hirschler)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.